Hello, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because that oh-so-familiar routine of meetings, deadlines, and conference calls has predictably returned. But you knew this would happen, yes? After all, the world keeps spinning. So what else to do but fire up the coffee kettle, brew a cup or three of stimulation, and dig in for another busy day. On that note, here are some items of interest to get you started. Hope you have a grand day and keep in touch. …

Pfizer (PFE) won Food and Drug Administration approval for an oral drug called tafamidis to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, Reuters says. Pfizer, which has touted the drug as a potential blockbuster product, set a list price of $225,000 a year for the medicine, which would be sold under the brand name Vyndaqel. It is the first medicine approved for the disease in the U.S., and analysts are forecasting annual sales to exceed $1 billion in 2024. Pfizer believes about 100,000 people in the U.S. have the condition, but most are not diagnosed.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy